Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-06

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multi-center, open-label, dose-esclation I/Ib clinical study to explore safety, efficacy an pharmacokinetics of proxalutamide in patients with metastatic breast cancer.

This study includes two stages, stage I: single- and multiple-dose tolerance and pharmacokinetic study; stage 2: preliminary efficacy and safety study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Irinotecan for Advanced and Metastatic Breast Cancer

NCT03562390

Breast Cancer

UNKNOWN PHASE2

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer

NCT04631835

Breast Cancer

UNKNOWN PHASE1

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

NCT05519059

Advanced or Metastatic Breast Cancer

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

NCT04398108

HER2 Positive Metastatic Breast Cancer

COMPLETED PHASE1

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

NCT03405168

Advanced Breast Cancer Antibiotic Stable Disease With a Trend of Progression

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multi-center, open-label, dose-esclation study.

Subjects will be enrolled to the 100mg, 200mg, 300mg, 400mg and 500mg group in turn. Unless DLT was found, the dose esclation will continue. 28 days of DLT observation period is needed after 7-day single dose administration, until disease progression, intolerable toxicities (AEs), or withdrawn consent.

After the completion of stage 1, 2 doses for the stage 2 will be determined. In stage 2, patients with AR-positive metastatic breast cancer will be selected to explore the efficacy and safety of proxalutamide, and biomarkers will be explored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Proxalutamide

Stage one - Dose climbing:

Each dose cohort will assess toxicity within the 35 days following the first dose of GT0918.

Stage two- the expansion cohort :

30 patients will be enrolled to the 200mg cohort . 15 patients will be enrolled to the 300mg cohort.

Group Type EXPERIMENTAL

Proxalutamide

Intervention Type DRUG

Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proxalutamide

Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years female;
2. Stage 1:Histology or cytology confirmed metastatic breast cancer, first-line chemotherapy or targeted therapy failure or intolerance

Stage 2: Histological or cytological confirmed metastatic breast cancer patients who failed or intolerant to anti-tumor therapy; have a positive AR test result;
3. At least one measurable lesion based on RECIST version 1.1 ;
4. ECOG performance status: 0-1;
5. Have a predicted life expectancy of greater than 3 months;
6. The functions of the important organs are confirmed with the following requirement:

* Hemoglobin (HGB) ≥ 90 g/L(no blood transfusion within 14 days );
* Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L；
* Platelets (PLT) ≥ 100×10\^9/L(If the coagulation function is normal,Platelets (PLT) ≥ 75×10\^9/L )；
* Total bilirubin (TBIL) ≤ 1.5× Upper limit of normal value (ULN) -Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine -
* Aminotransferase (ALT) ≤2.5× ULN
7. Understand and voluntarily sign the informed consent form；
8. Subject is willing and able to comply with all protocol required visits and assessments；

Exclusion Criteria

1. Pregnant, lactating women, or those who have fertility and are reluctant to take effective contraceptive measures;
2. Prior chemotherapy, radiation, targeted therapy ,androgen receptor inhibitors therapy (abiraterone,enzalutamide,etc )，other endocrine therapy ，and has acceptted traditional chinese herbal medicine treatment less than 4 weeks prior to the start of study medication.
3. Has severe cardiovascular disease
4. The toxicity of the previous treatment plan has not been restored before enrollment, and there is still non-hematologic toxicity of grade 1 or above (except for hair loss)
5. Known gastrointestinal disease or condition that affects the absorption of GT0918;
6. Known or suspected brain metastases, including the central nervous system and spinal cord compression or meningeal metastasis;
7. History of severe central nervous system diseases (including patients with epilepsy);
8. Known hypersensitivity to proxalutmide or its excipients.
9. Participated in clinical trials of other drugs or medical devices within one month prior to screening, or plan to participate in any other clinical trials during the study period;
10. Subjects with any other serious disease considered by the investigator not in the condition to enter into the trial;

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No